Clinical Trial Update: Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating MYOBLOC for treating sialorrhea in pediatric subjects has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sialorrhea

Drugs mentioned

• MYOBLOC (rimabotulinumtoxinB)

Snippet

Sponsor: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | Conditions: Sialorrhea | Phase 3 | Status: WITHDRAWN